NCT05845567View on ClinicalTrials.gov

The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

May 8, 2022

Study Completion Date

May 24, 2022

Conditions
Drug Drug Interaction
Interventions
DRUG

Givinostat

ITF2357 Givinostat 10mg/mL. Dose: 10 mg/mL; Dosage form: oral suspension.

DRUG

Clarithromycin

Clarithromycin 500 mg immediate-release oral film-coated tablet (Klacid®) was administered twice a day, in the morning and in the evening.

Trial Locations (1)

153

Hospital da Prelada, 3rd Floor & East Wing 4th Floor Rua Sarmento de Beires, Porto

Sponsors

Lead Sponsor

Italfarmaco
All Listed Sponsors
lead

Italfarmaco

INDUSTRY

NCT05845567 - The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2) | Biotech Hunter | Biotech Hunter